<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03669718</url>
  </required_header>
  <id_info>
    <org_study_id>ISA101b-HN-01-17</org_study_id>
    <nct_id>NCT03669718</nct_id>
  </id_info>
  <brief_title>A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study of Cemiplimab Versus the Combination of Cemiplimab With ISA101b in the Treatment of Subjects With HPV16-Positive Oropharyngeal Cancer (OPC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ISA Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ISA Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a blinded, placebo-controlled, randomized, phase 2 study in which subjects will&#xD;
      be randomly assigned 1:1 to cemiplimab plus placebo or cemiplimab plus ISA101b.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will assess the ability of ISA101b to improve Overall Response Rate in subjects&#xD;
      with HPV16 positive OPC, when combined with cemiplimab, an investigational anti-PD-1 antibody&#xD;
      being developed by Regeneron Pharmaceuticals. ISA101b is a therapeutic cancer vaccine that&#xD;
      induces specific immune responses to the oncogenic E6 and E7 antigens from HPV16. Trials in&#xD;
      HPV16 driven malignancies indicate it has activity in HPV16 driven malignancies including&#xD;
      oropharyngeal and cervical cancers. Cemiplimab, also known as REGN2810, is in late stage&#xD;
      trials and appears to have similar activity to approved anti PD-1 antibodies in a number of&#xD;
      malignancies .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 30, 2018</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>25months</time_frame>
    <description>Measured using RECIST 1.1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by NCI CTCAE v5.0 &quot;Number of participants with treatment-related adverse events as assessed by NCI CTCAE v5.0&quot;.</measure>
    <time_frame>25 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) by independent review in subjects randomized to receive ISA101b plus cemiplimab compared to placebo plus cemiplimab.</measure>
    <time_frame>25months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">194</enrollment>
  <condition>Squamous Cell Carcinoma of the Oropharynx</condition>
  <condition>HPV16 Positive</condition>
  <arm_group>
    <arm_group_label>Active ISA101b and cemiplimab.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ISA101b 3 times plus cemiplimab every 3 weeks for up to 24 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and cemiplimab</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 3 times plus cemiplimab every 3 weeks for up to 24 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ISA101b</intervention_name>
    <description>Every 3 weeks for a total of 3 times</description>
    <arm_group_label>Active ISA101b and cemiplimab.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cemiplimab</intervention_name>
    <description>Every 3 weeks for up to 24 months</description>
    <arm_group_label>Active ISA101b and cemiplimab.</arm_group_label>
    <arm_group_label>Placebo and cemiplimab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Every 3 weeks for a total of 3 times</description>
    <arm_group_label>Placebo and cemiplimab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females, ≥ 18 years of age.&#xD;
&#xD;
          -  Sign and date an Institutional Review Board/Independent Ethics Committee&#xD;
             (IRB)/(IEC)-approved written informed consent form (ICF) in accordance with regulatory&#xD;
             and institutional guidelines. This must be obtained before the performance of any&#xD;
             protocol-related procedures that are not part of normal subject care.&#xD;
&#xD;
          -  Be willing and able to comply with scheduled visits, treatment schedule, laboratory&#xD;
             testing, and other requirements of the study.&#xD;
&#xD;
          -  Diagnosed with histologically confirmed recurrent or metastatic HPV16 positive OPC,&#xD;
             whose tumors express PD-L1 (Combined Positive Score [CPS] ≥1) and who are candidates&#xD;
             for first line therapy with an PD-1 blocking antibody, AND subjects with recurrent or&#xD;
             metastatic HPV16 positive OPC with disease progression on or after platinum containing&#xD;
             chemotherapy.&#xD;
&#xD;
          -  HPV-16 genotyping will be determined by the specified central reference laboratory.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.&#xD;
&#xD;
          -  Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per&#xD;
             RECIST 1.1 criteria.&#xD;
&#xD;
          -  Prior curative radiation therapy must have been completed at least 4 weeks prior to&#xD;
             study drug administration. Prior focal palliative radiotherapy must have been&#xD;
             completed at least 2 weeks before study drug administration.&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy&#xD;
             test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin&#xD;
             [HCG]) within 24 hours prior to the start of study drug.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Subjects with previously untreated metastatic or unresectable, recurrent HPV16&#xD;
             positive OPC whose tumors do not express PD-L1 (CPS&lt;1) and who are therefore not&#xD;
             candidates for monotherapy with an anti-PD-1 antibody.&#xD;
&#xD;
          -  Subjects with known brain metastases or leptomeningeal metastases.&#xD;
&#xD;
          -  Any serious or uncontrolled medical disorder that, in the opinion of the investigator,&#xD;
             may increase the risk associated with study participation or study drug&#xD;
             administration, impair the ability of the subject to receive protocol therapy, or&#xD;
             interfere with the interpretation of study results.&#xD;
&#xD;
          -  History of other malignancy ≤ 3 years prior to entry into this trial with the&#xD;
             exception of basal cell or squamous cell skin carcinoma which were treated with local&#xD;
             resection only, or carcinoma in situ of the cervix, prostate or breast, or low grade&#xD;
             non-muscle invasive superficial bladder cancer (TaLG)/carcinoma in situ of the&#xD;
             bladder.&#xD;
&#xD;
          -  Subjects with active, known or suspected autoimmune disease. Subjects with vitiligo,&#xD;
             type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only&#xD;
             requiring hormone replacement, psoriasis not requiring systemic treatment, or&#xD;
             conditions not expected to recur in the absence of an external trigger are permitted&#xD;
             to enroll.&#xD;
&#xD;
          -  Subjects with a condition requiring immunosuppressive doses of systemic medication&#xD;
             such as steroids or absorbed topical steroids (doses ≥ 10 mg/day prednisone or&#xD;
             equivalent) or other immunosuppressive medications within 14 days of study drug&#xD;
             administration. Inhaled or topical steroids and adrenal replacement doses &lt; 10 mg&#xD;
             daily prednisone equivalents are permitted in the absence of active autoimmune&#xD;
             disease.&#xD;
&#xD;
          -  Prior treatment with an anti-PD-1 antibody (e.g., nivolumab, pembrolizumab,&#xD;
             cemiplimab), as well as an antibody targeting anti-PL-L1 anti-PD-L2, anti-CTLA-4&#xD;
             antibody, or any other antibody or drug specifically targeting T-cell co stimulation&#xD;
             or immune checkpoint pathways.&#xD;
&#xD;
          -  Prior treatment with more than one chemotherapy regimen for the management of&#xD;
             metastatic OPC.&#xD;
&#xD;
          -  Prior treatment with therapeutic anti-HPV vaccines including ISA101 or ISA101b.&#xD;
             Subjects may have received a preventive HPV vaccine.&#xD;
&#xD;
          -  All toxicities attributed to systemic prior anti-cancer therapy other than alopecia&#xD;
             and fatigue must have resolved to Grade 1 (NCI CTCAE) or baseline before&#xD;
             administration of study drug. Subjects with toxicities attributed to systemic prior&#xD;
             anticancer therapy that are not expected to resolve and result in long lasting&#xD;
             sequelae, such as neuropathy after platinum based therapy, are permitted to enroll.&#xD;
&#xD;
          -  History of allergy to ISA101/ISA101b study drug components, e.g., ISA101/101b,&#xD;
             Montanide, or Macrogolglycerol Ricinoleate, also known as cremophore.&#xD;
&#xD;
          -  History of allergy to cemiplimab and its excipients.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bonnie S. Glisson, MD, BS</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sonja Visscher</last_name>
    <phone>+31713322310</phone>
    <email>Visscher@isa-pharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erminia Massarelli, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Moores Cancer Center at the UC San Diego Health</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Gold, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain Algazi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Agulnik, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Douglas Adkins, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Cancer Institute</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45069</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muhammad Kashif Riaz, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Zandberg, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>M. D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bonnie Glisson, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael Santana-Davila, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Antwerp</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pol Specenier, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Grand Hopital de Chaleroi</name>
      <address>
        <city>Charleroi</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe Lonchay, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Clement, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Olomouc</name>
      <address>
        <city>Olomouc</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bohuslav Melichar, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nemocnice na Bulovce</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petra Holečková, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine Italiano, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerome Fayette, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital de la Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastien Salas, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondation Hospital Saint Joseph</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel Gatineau, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Even, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires Pitié Salpêtrière Charles Foix</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurelien Gobert, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franz-Georg Bauernfeind, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IKrankenhaus Nordwest gGmbH, nstitut für Klinisch-Onkologische Forschung</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salah-Eddin Al-Batran, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Dietz, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon Laban, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Magyar Honvédség Egészségügyi Központ</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zsuzsanna Emília Pápai, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Onkolgiai Klinika</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Arkosy, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Petz Aladar Megyei Oktat Krhz</name>
      <address>
        <city>Gyor</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamas Pinter, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szabolcs Szatmar Bereg Megyei Korhazak Es Egyetemi Oktatokorhaz</name>
      <address>
        <city>Nyiregyhaza</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jozsef Erfan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pecs Department of Oncotherapy</name>
      <address>
        <city>Pecs</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laszlo Mangel, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hetenyi Geza Korhaz-Rendelointezet</name>
      <address>
        <city>Szolnok</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tibor Csoszi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Paolo Polo Universitario</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daris Ferrari, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Licitra, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UOC Oncologia Medica Ospedale di Sondrio</name>
      <address>
        <city>Sondrio</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Bertolini, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Universitaria Integrata di Udine</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ciro Rossetto, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Antoni van Leeuwenhoek Ziekenhuis</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Paul Boer de, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leiden University Hospital</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marije Slingerland, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Radboud University Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carla Herpen, van, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lot Devriese, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clnic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Grau, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Duran i Reynals - Institut Catala dOncologia ICO</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miren Taberna, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irene Brana, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro Perez Segura, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beatriz Castelo Fernandez, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The 12 de Octubre University Hospital</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Antonio Núñez Sobrino, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitario Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisardo Ugidos de la Varga, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>Malaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Manuel Trigo Perez, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elvira del Barco Morillo, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marqués de Valdecilla Santander</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Almudena Garcia Castano, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden NHS Foundation</name>
      <address>
        <city>Chelsea</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Harrington, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>Sutton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Harrington, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beacon Centre Musgrove Park Hospital</name>
      <address>
        <city>Taunton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petra Jankowska, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>August 11, 2018</study_first_submitted>
  <study_first_submitted_qc>September 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2018</study_first_posted>
  <last_update_submitted>April 14, 2021</last_update_submitted>
  <last_update_submitted_qc>April 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cemiplimab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

